1. Pink Sheet

Government Pharma Investigations Target Pricing, Opioids, Trade Practices

 
• By Brenda Sandburg

While DOJ probes have declined in last few years, 13 of top 25 pharma companies are dealing with ongoing inquiries of marketing and pricing practices.

Business, Technology, Internet and network concept. Businessman working on the tablet of the future, select on the virtual display: Investigation

Once the fodder for billion dollar settlements, government investigations of the pharmaceutical industry have fallen off in the last few years. But behind the scenes the Department of Justice continues to probe several practices, including pricing, opioid marketing, and relationships with charities and pharmacy benefit managers (PBMs).

A look at recent Securities and Exchange Commission filings and financial statements of more than 20 of the top revenue generators in the pharma sector reveal the focus of government subpoenas and civil investigative demands

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

More from Pink Sheet

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.